The deal transforms XTL from a shell into an operating psychedelic biotech with clinical assets and manufacturing, but carries significant execution risk: shareholder approval, Nasdaq delisting appeal outcome, and milestone achievement are all uncertain. Monitor the shareholder vote and Nasdaq hearing decision closely — delisting would trigger renegotiation and likely depress the stock. The $1.5M private placement provides minimal runway for a company with seven clinical trials.
Price Chart
Executive Summary
XTL Biopharmaceuticals has entered into a definitive agreement to acquire 100% of Psyga Bio Ltd., a psychedelic biotechnology company with seven approved Phase 2a clinical trials and a GMP-ready manufacturing facility. The all-stock deal will issue XTL ADSs representing 40% of its outstanding shares to Psyga's shareholders, with additional milestone-based earnouts of up to 30% more. The transaction is subject to shareholder approval and Nasdaq delisting risk, as XTL received a Nasdaq deficiency notice in February 2026 for being a public shell.
Key Facts
- XTL to acquire 100% of Psyga Bio Ltd. in all-stock deal, issuing ADSs representing 40% of XTL's outstanding shares at closing.
- No cash consideration at closing; Psyga shareholders eligible for additional ADSs (10% each) upon achieving three clinical and commercialization milestones.
- Psyga has seven approved Phase 2a human clinical trials across mental health, neurological, and addiction indications.
- Psyga operates a licensed GMP-ready facility for botanical and synthetic psilocybin, Ibogaine, and other psychedelic APIs.
- XTL received a Nasdaq deficiency notice on Feb 27, 2026, deeming it a public shell; hearing held April 16, 2026, outcome pending.
- Transaction is an interested-party deal: XTL director Alexander Rabinovich holds ~24.9% of XTL and is Psyga's Chairman.
- XTL secured a $1.5M private placement commitment to fund the transaction, contingent on shareholder approval and closing.
- Audit committee and board approved the deal after receiving a fairness opinion from I.F.S. Consulting and Investments (2009) Ltd.
- President Trump signed an Executive Order on April 18, 2026, accelerating FDA pathways for psychedelic therapies.
- Psyga's shareholders will be subject to a 6-month escrow/lock-up on issued ADSs.
Financial Impact
All-stock acquisition with no cash consideration; Psyga shareholders receive 40% of XTL's outstanding shares at closing, plus up to 30% additional shares upon milestone achievement. XTL also secured a $1.5M private placement commitment.
Risk Factors
- Nasdaq delisting risk: XTL received a deficiency notice as a public shell; hearing outcome pending — delisting would require deal renegotiation.
- Shareholder approval required for interested-party transaction; failure to obtain within 60 days allows XTL to terminate without liability.
- Milestone-based earnouts are contingent on clinical trial commencement and success, which carry high biotech failure risk.
- Significant dilution: Psyga shareholders receive 40% of XTL at closing, with potential for additional 30% upon milestones.
- No financial statements for Psyga disclosed in the filing; valuation and financial health of the target are opaque.
- XTL's market cap is only $5M; the $1.5M private placement is large relative to current valuation but small for clinical-stage operations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-048875 |
| Document: ea0288126-6k_xtlbio.htm | 0001213900-26-048875 |
| Document: ea028812601ex99-2.htm | 0001213900-26-048875 |
| Document: 0001213900-26-048875-index-headers.html | 0001213900-26-048875 |
| Document: 0001213900-26-048875-index.html | 0001213900-26-048875 |
| Document: 0001213900-26-048875.txt | 0001213900-26-048875 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 6-K | $1.91 | awaiting T+60 | — | $1.82 (−4.71%) |
Jun 30, 2026 16w ago | 20-F | $2.49 $2.41 | ▲ +3.21% | ▲ +6.08% | $1.82 (+26.91%) |
Jun 29, 2026 17w ago | 6-K | $2.73 $2.20 | ▼ −19.41% | ▼ −22.23% | $1.82 (−33.33%) |
May 22, 2026 22w ago | 6-K | $2.38 $2.98 | ▼ −25.21% | ▼ −22.49% | $1.82 (+23.53%) |
May 7, 2026 24w ago | 6-K | $2.67 $2.86 | ▲ +7.15% | ▲ +3.31% | $1.82 (−31.84%) |
Apr 29, 2026 25w ago | 6-K | $3.56 $2.94 | ▼ −17.42% | ▼ −21.53% | $1.82 (−48.88%) |
Apr 29, 2026 25w ago | Press Release | $3.56 $2.94 | ▼ −17.42% | ▼ −21.53% | $1.82 (−48.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers